Ballicules.com

Doxepin

SINEQUAN

What it isTricyclic with very high H1 affinity; at low dose an insomnia agent, at high dose an antidepressant.

Why this oneAt 3 to 6 mg it is essentially a pure H1 antagonist, giving sleep maintenance without anticholinergic or dependence effects.

What limits itAt antidepressant doses it becomes a full tricyclic with all the anticholinergic and overdose liability. The dose determines which drug it is.

FDA-approved for

Off-label

FDA label

FDA dosingPopulationStartTargetMax
Insomnia (sleep maintenance)Adults6 mg QHS6 mg QHS6 mg/day
Insomnia (sleep maintenance)Elderly ≥65 y3 mg QHS3–6 mg QHS6 mg/day

Renal Undefined

Hepatic Initiate at 3 mg; monitor closely for daytime effects

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy No established increased risk of major birth defects/miscarriage; risk of poor neonatal adaptation with third-trimester TCA exposure

Lactation Doxepin/nordoxepin present in milk; reports of sedation, respiratory depression, poor feeding, hypotonia — breastfeeding not recommended

⚠ BOXED WARNING

Cost, est. cash$5–$150/month

Generic entry1986

Classes and tags

Clinical profile

Therapeutic safety burden3 / 4
Overdose danger4 / 4
Weight-gain liability2 / 4
Sedation liability3 / 4
QT / Torsades1 / 4
Direct muscarinic antagonism3 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilityTricyclic anticholinergic and cardiac toxicity become life-threatening in overdose.

Active metabolites

Mechanism of action: Doxepin ballicule

Doxepin ballicule: receptor binding, kinetics and half-life diagram

Open Doxepin in the interactive console ↗

Memory aids: mascots and interaction avatars

Doxepin SINEQUAN, SILENOR mascot mnemonic cartoon
“Box with pins”
Doxepin CYP2C19 substrate avatar
CYP2C19 substrate
Doxepin CYP2D6 substrate avatar
CYP2D6 substrate

Open Doxepin in the interactive console ↗